Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Many patients with diabetes mellitus show a moderate reduction in bone mass. Our recent in vitro studies showed that sustained exposure of osteoblast-like MG-63 cells to high glucose by itself impairs their functions partly via the polyol pathway. To investigate the role of hyperglycemia in the etiology of diabetic osteopenia in vivo separately from insulin deficiency, we determined whether epalrestat, an aldose reductase (AR) inhibitor (ARI), lessens the abnormalities in calcium (Ca) metabolism in galactose-fed rats. Weight gain was impaired in the rats, which was not altered by epalrestat. Galactose feeding temporarily enhanced bone resorption as reflected by increased biochemical markers for bone resorption (urinary excretion of pyridinoline [PYR] and deoxypyridinoline [DPYR]) at 1 to 3 months, which were significantly decreased by epalrestat. Epalrestat also restored the positive correlation between a bone-formation marker (serum osteocalcin [OC]) and a bone-resorption marker (urinary DPYR excretion) at 6.5 months. Histomorphometric analysis of bone performed 6.5 months after galactose feeding showed that both the bone volume and osteoblast numbers in the tibia, which were significantly suppressed by galactose feeding, were partly restored to a significant extent by the simultaneous administration of epalrestat. In summary, epalrestat partially protected against the development of osteoblast dysfunction and reduced the temporary increase in biochemical markers for bone resorption induced by galactose feeding, with a resultant increase in bone volume, suggesting that the polyol pathway may be intimately involved in the development of abnormal bone metabolism in galactose-fed rats.
Second Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan.
M
M
Inaba
M
M
Terada
Y
Y
Nishizawa
A
A
Shioi
E
E
Ishimura
S
S
Otani
H
H
Morii
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000596:Amino Acids / Q000652:urine; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000652:urine; D004435:Eating / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005690:Galactose; D008297:Male; D015675:Osteocalcin / Q000097:blood; D011108:Polymers / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D053778:Thiazolidines; D013977:Tibia / Q000187:drug effects / Q000473:pathology
D000596:Amino Acids; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D011108:Polymers; D053778:Thiazolidines; C024617:polyol; D015675:Osteocalcin; C038131:epalrestat; C015484:pyridinoline; D012236:Rhodanine; C036020:deoxypyridinoline; D000449:Aldehyde Reductase; D002118:Calcium; D005690:Galactose